Innehållet nedan modereras inte i förväg och omfattas därmed inte av webbplatsens utgivningsbevis.
Dela sida
Sponsrat innehåll

Cadherins: Emerging Targets for Cancer Therapy

Cadherins play indispensable roles in both normal physiological processes and the development of various diseases. Several cadherins have emerged as promising targets for treating cancers and other diseases. Sino Biological offers the most comprehensive selection of recombinant cadherin proteins and corresponding antibodies, providing invaluable tools for advancing biomedical research.

Learn more about cadherins.

Featured Cadherin Products

Sino Biological has developed a panel of high-quality recombinant cadherin proteins, including CDH1 (E-Cadherin), CDH2 (N-Cadherin), CDH3 (P-Cadherin), CDH4 (R-Cadherin), CDH5 (VE-Cadherin), CDH6 (K-Cadhedin), CDH8, CDH12, CDH13 (H-Cadherin), CDH16 (Ksp-Cadherin), CDH17 (LI-Cadherin), and CDH18, with broad coverage of species and tags and highly cited in reputable journals. The antibodies against cadherins are also available with a variety of applications, such as ELISA, IHC-P, ICC/IF, FCM, WB, and IP.

Download poster to gain more valuable insights for cadherins.

Find out more drug targets in different research fields.

Sino Biological Europe GmbH
Düsseldorfer Str. 40
65760 Eschborn
VAT nummer: DE323950120


Sino Biological Europe GmbH

Sänd till en kollega